<DOC>
	<DOCNO>NCT01640535</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy Concomitant Montelukast Sodium Levocetirizine Dihydrochloride superior Levocetirizine Montelukast monotherapies compare safety tolerability Concomitant Montelukast Sodium Levocetirizine Dihydrochloride Levocetirizine Montelukast monotherapies Perennial Allergic Rhinitis ( PAR ) patient .</brief_summary>
	<brief_title>Efficacy Safety Concomitant Montelukast Sodium Levocetirizine Dihydrochloride Perennial Allergic Rhinitis ( PAR ) Patients</brief_title>
	<detailed_description>randomize , double-blind , active-controlled , multicenter , phase 3 trial</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Patients least 2 year history PAR prior study Positive result skin prick test Patients provide signed write informed consent form Patients able willing complete subject diary Patients agree maintain consistency surroundings throughout study period At Visit , 2 patient whose symptom score record subject diary meet following last one week baseline period A.Daily mean 6 point Daytime Nasal Symptom Score ( maximum 12 point ) B.Daily mean 1.8 point Daytime Nasal Obstruction Symptom Score ( maximum 3 point ) Patients also nonallergic rhinitis different cause . Patients severe asthma meet following . Presence nasal polyp clinically important nasal anomaly . History acute â€¢ chronic sinusitis within 30 day Visit 1 History intranasal / eye surgery within 3 month Visit 1 Initiation immunotherapy dose modification within 1 month prior Visit 1 Upper respiratory infection include cold systemic infection within 3 week Visit 1 . Chronic use tricyclic antidepressant , beta agonist , bronchodilator , etc . may affect efficacy study drug At Visit 2 , patient record Daytime Nasal Symptom Scores few 4 day subject diary last one week baseline period</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>PAR</keyword>
</DOC>